The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
 
Emily Nash Smyth
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Samuel Whipple
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Mark Guinter
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
Research Funding - Lilly (Inst)
 
Nadine Haddad
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Wenxian Piao
Employment - Flatiron Health
Stock and Other Ownership Interests - Roche
Research Funding - Lilly (Inst)
 
Zhanglin Lin Cui
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Arjun Vasant Balar
Employment - Loxo/Lilly
Stock and Other Ownership Interests - Lilly
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Seagen